These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

655 related items for PubMed ID: 7768629

  • 1. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
    Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ.
    Int J Cancer; 1995 May 29; 61(5):597-600. PubMed ID: 7768629
    [Abstract] [Full Text] [Related]

  • 2. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ, Rha SY, Chung HC, Yoo NC, Roh JK, Yang WI, Lee KS, Min JS, Kim BS, Chung HC.
    Int J Mol Med; 2000 Sep 29; 6(3):301-5. PubMed ID: 10934293
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun 29; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

  • 4. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
    Nozaki S, Endo Y, Kawashiri S, Nakagawa K, Yamamoto E, Yonemura Y, Sasaki T.
    Oral Oncol; 1998 Jan 01; 34(1):58-62. PubMed ID: 9659521
    [Abstract] [Full Text] [Related]

  • 6. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Takada A, Nakamura S.
    Cancer; 1999 Dec 15; 86(12):2602-11. PubMed ID: 10594855
    [Abstract] [Full Text] [Related]

  • 7. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 15; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 8. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul 15; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 15; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 13. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB.
    J Cancer Res Clin Oncol; 2000 Nov 15; 126(11):641-6. PubMed ID: 11079728
    [Abstract] [Full Text] [Related]

  • 14. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V, Brünner N.
    Clin Exp Metastasis; 1996 May 15; 14(3):297-307. PubMed ID: 8674284
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
    Gershteĭn ES, Kushlinskiĭ NE.
    Vestn Ross Akad Med Nauk; 1999 May 15; (8):58-61. PubMed ID: 10487126
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.